Lead Sponsor

Novo Nordisk A/S

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

•Subjects with moderate to severe stable chronic plaque psoriasis for at least 6 months, with or without psoriatic arthritis
•Affected body surface area (BSA) greater than or equal to 15%
•Physician's Global Assessment (PGA) score of 3 or more
•Female subjects of non-childbearing potential or postmenopausal for at least 1 year. Male subjects must agree to use effective method of birth control
•Body Mass Index (BMI) less than or equal to 38.0 kg/m2

•Concomitant anti-psoriatic treatment
•Infectious disease requiring systemic anti-infectious treatment within the 2 weeks prior to administration of trial drug
•Known history of Human Immunodeficiency Virus (HIV)
•Hepatitis B and/or C (determined by test)
•Live virus or bacteria vaccines within the last month before drug administration
•Known active herpes/herpes zoster/cold sores
•Kidney insufficiency
•Liver insufficiency
•Lymphoproliferative disease
•History or signs of malignancy within the last 5 years

Related studies

NCT07290569 · Plaque Psoriasis

NCT07455578 · Autoimmune Diseases, Rheumatoid Arthritis (RA), and more

NCT06425549 · Moderate to Severe Plaque Psoriasis

NCT07571473 · Surgical Stress Response, Inflammation, and more

NCT07011394 · Diagnosis, Inflammation, and more

First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects